|
ÇѾç´ë±¸¸®º´¿ø Ç÷¾×Á¾¾ç³»°ú ÇãÁØ¿µ ±³¼ö°¡ '2020³â Çѱ¹¾ÏÇмúÀç´Ü Çмú»ó'À» ¼ö»óÇß´Ù. ÇãÁØ¿µ ±³¼ö´Â Oncoimmunology (IF=5.33)¿¡ °ÔÀçµÈ \'Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment\' Á¦¸ñÀÇ ³í¹®À¸·Î Çмú»óÀ» ¹Þ¾Ò´Ù. |